Encapsulated bioactive mitochondria for transplantation in cells.
OUR STORY
For mitochondria transplantation therapy to related diseases.
Dysfunctions in mitochondria are associated with an increasingly large number of diseases and disorders, such as neuromuscular disorders, cardiovascular diseases, metabolic syndrome, and cancer. With transplantation, the normal mitochondrial function can be revitalized with diseased cells.
Our Comitell® technology will be a fundamental tool to enable mitochondria transplantation-based therapy by providing long-lasting bioactivity and high-efficiency delivery.
The good intracellular delivery efficiency and the possibility to use in vivo administration make our encapsulation technology of broad interest for pharmaceutical industry.
Mitochondrias
are organelles with tiny structures, and they perform significant functions within cells, including biosynthesis, cell apoptosis, cell signal transduction, and bioenergy metabolism pathway (aerobic oxidation of glucose, oxidation of fatty acid), and are responsible for the redox state. Mitochondrial dysfunction is associated with an increasingly large number of heterogeneous clinical presentations and disorders, such as neuromuscular disorders, cardiovascular disorders, metabolic syndrome, cancer, and obesity.
Our Team
has developed an encapsulation technology called Comitell® for mitochondria. Comitell® is an effective and unique approach that can maintain the mitochondria bioactivity for a long time and significantly improve the intracellular delivery efficiency, which has not been achieved before. This encapsulation technology can be used for mitochondria transplantation/delivery therapy for treating the broad scope of mitochondrial-related diseases.
Our Mission
By staying at the forefront of this rapidly advancing field, we can make a meaningful impact on the lives of millions of people worldwide suffering from debilitating diseases.
Our partners
